文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

达格列净对TAVI术后主动脉瓣狭窄患者生活质量的影响

Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

该研究为DapaTAVI试验的预设分析,纳入964例接受TAVI的主动脉瓣狭窄患者,评估达格列净对KCCQ健康状态评分的影响。结果显示两组KCCQ评分均有改善,但达格列净组在3个月和12个月时未显示额外获益,12个月时临床有意义改善比例分别为43.4%和45.4%。

要点

  • TAVI术后患者KCCQ评分显著改善,但加用达格列净未带来额外健康状态获益。
  • 3个月和12个月KCCQ改善的OR分别为0.96和1.03,均无统计学差异。
  • 达格列净的临床获益在基线KCCQ全范围内相似。

核心结论

  • TAVI与KCCQ评分大幅改善相关,但术后加用达格列净相比标准治疗未额外改善健康状态。

研究设计与样本

  • DapaTAVI试验的预设分析,随机分配患者接受或不接受达格列净,共964例有基线KCCQ评分。

主要发现

  • 两组KCCQ评分均改善,3个月改善OR 0.96(95%CI 0.72-1.26,P=0.745),12个月OR 1.03(95%CI 0.83-1.27,P=0.819)。
  • 12个月时达格列净组与对照组KCCQ改善>50分的比例分别为43.4%和45.4%。
  • 达格列净的临床获益在基线KCCQ全范围内相似。

关键数值与推荐

  • 基线KCCQ平均39.5±22.2。
  • 临床有意义改善定义为KCCQ改善>50分。

临床怎么用

  • TAVI术后标准治疗可显著改善健康状态,不推荐仅为改善生活质量而常规加用达格列净。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) experience a great improvement in health status. Dapagliflozin has been shown to reduce death and heart failure (HF) in these patients. However, the impact of dapagliflozin on improving health status after TAVI is unknown. OBJECTIVES: In this prespecified analysis of the DapaTAVI (Dapagliflozin After Transcatheter Aortic Valve Implantation) trial, we examined the effects of dapagliflozin on health status by using the Kansas City Cardiomyopathy Questionnaire (KCCQ). METHODS: The DapaTAVI trial randomized patients undergoing TAVI to receive or not receive dapagliflozin. We assessed the change in KCCQ score from baseline to 3 and 12 months by using an ordinal logistic regression model. Additionally, we analyzed the effect of dapagliflozin on the composite of death or worsening HF by baseline KCCQ score. RESULTS: A total of 964 patients had baseline KCCQ scores (mean 39.5 ± 22.2). Patients in both arms of the study exhibited improvements in KCCQ score, without significant differences between groups in the change in KCCQ score at 3 or 12 months (3-month OR for improvement: 0.96; 95% CI: 0.72-1.26; P = 0.745; 12-month OR: 1.03; 95% CI: 0.83-1.27; P = 0.819). At 12 months, similar proportions of patients in the dapagliflozin and control groups showed clinically meaningful improvements, with 43.4% vs 45.4%, respectively, improving by >50 points. The clinical benefits of dapagliflozin after TAVI appeared to be similar across the full range of baseline KCCQ scores. CONCLUSIONS: TAVI was associated with a substantial improvement in KCCQ scores. However, the addition of dapagliflozin following the procedure did not confer an additional benefit in health status compared with standard care. (Dapagliflozin After Transcatheter Aortic Valve Implantation [DapaTAVI]; NCT04696185).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bonanad-Lozano C, García Blas S, Amat-Santos I, et al. Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. 2025. PMID: 41062227. doi:10.1016/j.jacc.2025.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。